A Double-Blind, Placebo-Controlled Dose Escalation Study of the Administration of Multiple Intravenous Doses of RSLV-132 in Subjects With Systemic Lupus Erythematosus

Trial Profile

A Double-Blind, Placebo-Controlled Dose Escalation Study of the Administration of Multiple Intravenous Doses of RSLV-132 in Subjects With Systemic Lupus Erythematosus

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2016

At a glance

  • Drugs RSLV 132 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Proof of concept
  • Sponsors Resolve Therapeutics
  • Most Recent Events

    • 26 May 2016 Results will be presented at International Rheumatology Conference, as per Resolve Therapeutics media release.
    • 10 Feb 2016 Results published in the Resolve Therapeutics Media Release
    • 08 Dec 2015 Trial phase changed from II to I, Trial focus changed from TU to AR as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top